Short answers, pulled from the story.
Bristol Myers Squibb was formed by the 1989 merger of two older companies rather than by a single founder. Squibb was founded in 1858 by Edward Robinson Squibb in Brooklyn, New York, while Bristol-Myers grew out of the Clinton Pharmaceutical company, purchased in 1887 by William McLaren Bristol and John Ripley Myers.
Eliquis, the brand name for apixaban, is prescribed to people with atrial fibrillation. It was the company's single largest source of revenue, making up almost 30% of Bristol Myers Squibb's 2025 revenue.
Bristol-Myers and Squibb merged in 1989 to form Bristol-Myers Squibb.
Bristol Myers Squibb is headquartered in Princeton, New Jersey. Its research and development sites also include Lawrence, Summit, and New Brunswick in New Jersey, Redwood City in California, and Seville in Spain, among other locations.
FBI agents raided Bristol Myers Squibb's corporate offices in July 2006 on charges of collusion centered on the company's distribution of Plavix. The dispute led the court-appointed monitor to push for the removal of then chief executive Peter Dolan later that year, and the company announced his departure the same day.
Bristol Myers Squibb acquired Celgene for $74 billion, or $95 billion including debt, in November 2019. To secure regulatory approval for the deal, Amgen separately bought Celgene's drug Otezla for $13.4 billion.